Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

PubMed Journals Articles About "Anthera Halts VISTA Heart Drug Trial" RSS

04:44 EDT 25th April 2014 | BioPortfolio

Anthera Halts VISTA Heart Drug Trial PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Anthera Halts VISTA Heart Drug Trial articles that have been published worldwide.

More Information about "Anthera Halts VISTA Heart Drug Trial" on BioPortfolio

We have published hundreds of Anthera Halts VISTA Heart Drug Trial news stories on BioPortfolio along with dozens of Anthera Halts VISTA Heart Drug Trial Clinical Trials and PubMed Articles about Anthera Halts VISTA Heart Drug Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Anthera Halts VISTA Heart Drug Trial Companies in our database. You can also find out about relevant Anthera Halts VISTA Heart Drug Trial Drugs and Medications on this site too.

Showing "Anthera halts VISTA heart drug trial" PubMed Articles 1–25 of 11,000+

Extremely Relevant

Acute coronary syndromes: Targeting inflammation-what has the VISTA-16 trial taught us?

An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.

Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischem...

Relevant

Pharmacokinetics of Lacosamide and Omeprazole Coadministration in Healthy Volunteers: Results from a Phase I, Randomized, Crossover Trial.

The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.

Chinese medicine shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial.

To evaluate the efficacy and safety of Shensong Yangxin (SSYX) in patients with bradycardia arrhythmias, a randomized, double-blind, and placebo-controlled study was conducted. Patients with bradycardia were randomly assigned to receive either SSYX (trial group, n = 115) or placebo (control group, n = 104) for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, and hepatic and renal function were evaluated at baseline and after treatment. Results showed that the average heart rate, the fastest...

Changes in Geographic Variation in the Use of Percutaneous Coronary Intervention for Stable Ischemic Heart Disease After Publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial.

Drug Use Trajectories After a Randomized Controlled Trial of MTFC: Associations with Partner Drug Use.

Trajectories of drug use were examined in a sample of women with prior juvenile-justice system involvement. One hundred fifty-three young women who participated in a randomized controlled trial of Multidimensional Treatment Foster Care (MTFC) in adolescence were assessed on five occasions over a 24-month period in young adulthood (mean age = 22.29 years at T1). Participants assigned to the MTFC condition during adolescence reported greater decreases in drug use than girls assigned to the treatment as usual...

Zebrafish heart failure models for the evaluation of chemical probes and drugs.

Abstract Heart failure is a complex disease that involves genetic, environmental, and physiological factors. As a result, current medication and treatment for heart failure produces limited efficacy, and better medication is in demand. Although mammalian models exist, simple and low-cost models will be more beneficial for drug discovery and mechanistic studies of heart failure. We previously reported that aristolochic acid (AA) caused cardiac defects in zebrafish embryos that resemble heart failure. Here, w...

Severe Decrease of Cyclosporine Levels in a Heart Transplant Recipient Receiving the Direct Thrombin Inhibitor Argatroban.

: This case report is about a suspected interaction between argatroban, a direct thrombin inhibitor, and cyclosporine, which occurred in a 60-year-old patient after a second heart transplantation. We explored 4 possible mechanisms of interaction, which are an analytical interference, an idiopathic hemodilution, an increase of renal and hepatic clearance, and a metabolic drug-drug interaction.

Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.

Hospitalization for worsening heart failure (HF) is known to increase mortality and morbidity risk and has been frequently used as an endpoint in randomized clinical trials. Whether outpatient management of HF exacerbation carries similar prognostic and therapeutic information is less well known, but could be important for the design of trials that use HF hospitalization as an endpoint.

A Randomised Controlled Trial of Catheter Ablation versus Medical Treatment of Atrial Fibrillation in Heart Failure (THE CAMTAF TRIAL).

-Restoring sinus rhythm in patients with heart failure (HF) and atrial fibrillation (AF) may improve left ventricular (LV) function and HF symptoms. We sought to compare the impact of a catheter ablation strategy with that of a medical rate control strategy in patients with persistent AF and HF.

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

Management of diabetic patients with heart failure is a complex endeavor. The initial reluctance to use metformin in these patients has given way to a broader acceptance after clinical trials and meta-analyses have revealed that some of the insulin-sensitizing agents lead to adverse cardiovascular events. We have proposed that an increase of substrate uptake by the insulin-resistant heart is detrimental because the heart is already flooded with fuel. In light of this evidence, metformin offers a unique safe...

Ageing is a risk factor in imatinib mesylate cardiotoxicity.

Chemotherapy-induced heart failure is increasingly recognized as a major clinical challenge. Cardiotoxicity of imatinib mesylate, a highly selective and effective anticancer drug belonging to the new class of tyrosine kinase inhibitors, is being reported in patients, some progressing to congestive heart failure. This represents an unanticipated challenge that could limit effective drug use. Understanding the mechanisms and risk factors of imatinib mesylate cardiotoxicity is crucial for prevention of cardiov...

Totally Percutaneous Endovascular Abdominal Aortic Aneurysm Repair: 30-Day Results from the Independent Access-Site Closure Study of the PEVAR Trial.

Clinical Trial Design in Contemporary Device Studies in Heart Failure: Is There A Gold Standard?

The assessment of the efficacy and safety of implantable cardiac devices used for the management of heart failure is complicated by procedural challenges. We present an overview of the advantages and disadvantages of different clinical trial designs, and discuss investigator and patient blinding. We conclude that blinding is optimal, but methodologically difficult. Until rules for and assessment of blinding are developed or surrogate measures are considered acceptable from a regulatory standpoint, an open l...

The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.

Obstructive sleep apnea (OSA) and hypertension are well-known cardiovascular risk factors. Their control could reduce the burden of heart disease across populations. Several drugs are used to control hypertension, but the only consistently effective treatment of OSA is continuous positive airway pressure. The identification of a drug capable of improving OSA and hypertension simultaneously would provide a novel approach in the treatment of both diseases.Methods/design: This is a randomized double-blind clin...

The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children.

Pediatric populations continue to be understudied in clinical drug trials despite the increasing use of pharmacotherapy in children, particularly with psychotropic drugs. Most pertinent to the clinical selection of drug interventions are trials directly comparing drugs against other drugs. The aim was to measure the prevalence of active drug comparators in neuropsychiatric drug trials in children and identify the effects of funding source on comparator selection. We analyzed the selection of drugs and drug...

FDA halts then allows sales of Ariad's leukemia medication.

Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design

The Absorb everolimus-eluting bioresorbable vascular scaffold (AbsorbBVS) is a completely resorbable device engineered to overcome the limitations of permanent metallic stents, providing temporary scaffolding and antiproliferative drug delivery for the treatment of obstructive coronary artery disease.

Polypharmacy in Heart Failure Patients.

In heart failure (HF), the progressive use of multiple drugs and a complex therapeutic regimen is common and is recommended by international guidelines. With HF being a common disease in the elderly, patients often have numerous comorbidities that require additional specific treatment, thus producing a heavy pill burden. Polypharmacy, defined as the chronic use of five or more medications, is an underestimated problem in the management of HF patients. However, polypharmacy has an important impact on HF trea...

Dabigatran versus warfarin in patients with mechanical heart valves: reply.

Christensen and Larsen suggest that patients randomized to receive warfarin in the recently published RE-ALIGN randomized trial (1) were sub-optimally managed, citing lack of use of aspirin and poor control of anticoagulation. The RE-ALIGN trial was conducted in a real world setting and left responsibility for use of aspirin and the control of warfarin anticoagulation to the local investigators. Most of the evidence for using aspirin in combination with a vitamin K antagonist for patients with mechanical he...

CardioPulse Articles * European Journal of Heart Failure Editor-in-Chief retires * Profile: Dirk J. van Veldhuisen, Professor and Chairman of Cardiology at the University Medical Centre, Groningen, Netherlands * Book Review * Fast facts: Cardiac Arrhythmias * Christmas Greetings 2013 * Echocardiography-guided cardiac resynchronization therapy trial stopped prematurely * Consensus statement on paed

Positive Results for Drug Combo in I-SPY 2 Trial.

In results from one part of the I-SPY 2 trial announced at the 2013 San Antonio Breast Cancer Symposium, neoadjuvant veliparib plus carboplatin improved outcomes for women with triple-negative breast cancer.

Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings.

Dopamine D2 receptor agonists represent a first line treatment option in young patients with signs and symptoms of idiopathic Parkinson's disease. An association between the use of D2 receptor agonists in Parkinson's disease patients and heart failure has been reported. The identification of the underlying mechanism is needed to minimize the resultant cardiovascular morbidity. In a phase I clinical trial, a D2 receptor agonist (pramipexole) was administered to 52 healthy male subjects following a dose escal...

Mediterranean diet and heart rate: The PREDIMED randomised trial.

Echocardiography-guided cardiac resynchronization therapy trial stopped prematurely.


Search BioPortfolio:
Advertisement

PubMed Database Quicklinks

Advertisement